Prostate cancer, biological therapy, signal transduction inhibitors and anti-angiogenesis agents.
New systemic approaches to the treatment of prostate cancer, biological therapy (including vaccines and antibodies), signal transduction inhibitors and anti-angiogenesis agents were the focus of these ASCO sessions.